Incidence of hemorrhagic complications after intravitreal bevacizumab (Avastin) or ranibizumab (Lucentis) injections on systemically anticoagulated PATIENTS

Retina

Volumn 30, Issue 9, 2010, Pages 1386-1389

  Mason, John O ^a,b   Frederick, Paul A ^b   Neimkin, Michael G ^b   White, Milton F ^a,b   Feist, Richard M ^a,b   Thomley, Martin L ^a,b   Albert, Michael A ^a,b  

^a Retina Consultants Alabama   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

anti VEGF; anticoagulants; Avastin; bevacizumab; Coumadin; hemorrhagic complications; intravitreal injection; Lucentis; Plavix; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CLOPIDOGREL; RANIBIZUMAB; WARFARIN;

AGED; ARTICLE; CHOROID HEMORRHAGE; CONTROLLED STUDY; ENDOPHTHALMITIS; EYE SURGERY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; IRITIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RETINA MACULA HEMORRHAGE; RISK FACTOR; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASPIRIN; CHOROIDAL NEOVASCULARIZATION; EYE HEMORRHAGE; FEMALE; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; TICLOPIDINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WARFARIN;

EID: 77958588436     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181e09739     Document Type: Article

References (24)

1. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1334-1349. (Pubitemid 44702055)
2. Angulo Bocco MC, Glacet-Bernard A, Zourdani A, Coscas G, Soubrane G. Intravitreous injection: retrospective study on 2028 injections and their side effects. J Fr Ophthalmol 2008; 31:693-698.
3. Charles S, Rosenfeld PJ, Gayer S. Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections. Retina 2007;27:813-815. (Pubitemid 47479373)
4. Meyer CH, Callizo J, Mennel S, Kussin A. Perioperative management of anticoagulated patients undergoing repeated intravitreal injections. Arch Ophthalmol 2007;125:994. (Pubitemid 47076454)
5. Parkin B, Manners R. Aspirin and warfarin therapy in oculoplastic surgery. Br J Ophthalmol 2000;84:1426-1427.
6. Alwitry A, King AJ, Vernon SA. Anticoagulation therapy in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol 2008; 246:891-896.
7. Narendran N, Williamson TH. The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery. Acta Ophthalmol Scand 2003;81:38-40. (Pubitemid 36621902)
8. Flaxel CJ, Blach RK. Aspirin is a hazard for vitreoretinal surgery [letter]. Br J Ophthalmol 1996;80:486.
9. Avastin Prescribing Information, Genentech Inc. 2009. Available at: http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. Accessed August 1, 2009.
10. Lin RC, Rosenfeld PJ. Antiangiogenic therapy in neovascular age-related macular degeneration. Int Ophthalmol Clin 2007; 47:117-137. (Pubitemid 46145443)
11. Ahmadi AA, Chuo JY, Banashkevich A, Ma PE, Maberley DA. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Can J Ophthalmol 2009;44:154-159.
12. Isaacs T, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intra-vitreal injection of bevacizumab (Avastin). Clin Exp Oph-thalmol 2006;34:802-803. (Pubitemid 44650158)
13. Mason JO, Albert MA, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006;26:356-357. (Pubitemid 44318197)
14. Mason JO 3rd, Albert MA Jr, Mays A, Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006;26:839-841. (Pubitemid 44386115)
15. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354. (Pubitemid 44318195)
16. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007;16:437-439. (Pubitemid 47263045)
17. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizu-mab in a patient with neovascular glaucoma. Ophthal Surg Lasers Imaging 2006;37:144-146.
18. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005. (Pubitemid 44973218)
19. Zlateva GP, Javitt JC, Shah SN, Zhou Z, Murphy JG. Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the Medicare population. Retina 2007;27:1292-1299. (Pubitemid 350211540)
20. Rosenfeld PJ, Brown DM, Heier JS; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
21. Brown DM, Kaiser PK, Michels M; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
22. Dayani PN, Siddiqi OK, Holekamp NM. Safety of intravitreal injections in patients receiving warfarin anticoagulation. Am J Ophthalmol 2007;14:451-452.
23. Horn W, Hoerauf H. Intravitreal injections during anticoagulant treatment. Klin Monatsbl Augenheilkd 2008;225:217-219. (Pubitemid 351529695)
24. Meyer CH, Eter N. Incidence of ocular hemorrhages in anticoagulated patients receiving repeated intravitreal injections. Am J Ophthalmol 2007:144:451-453